Immuron (ASX: IMC) Secures Exclusive PROIBS US Distribution Deal

Immuron Limited has signed an exclusive agreement to distribute digestive-health product PROIBS® in the United States.

The agreement with Sweden’s Calmino group AB extends a partnership that already covers Australia. Immuron launched PROIBS® in Australia during the 2026 financial year.

No launch date, financial terms, sales targets or minimum purchase commitments were disclosed. The announcement also did not provide details about planned US sales channels.

A Larger Market for the Portfolio

Immuron is targeting part of the US digestive and gut-health supplement market with PROIBS®. That broader market is valued at $4.16 billion, according to Mordor Intelligence data cited by the company.

PROIBS® is a medical device used for abdominal pain, bloating and unsettled bowel movements. Those bowel symptoms can include diarrhoea, constipation or both.

The product contains AVH200®, which is derived from the Aloe barbadensis Mill plant. Its gel-forming components support the intestinal mucosal barrier, according to the announcement.

Immuron said PROIBS® is suitable for long-term use and has an excellent safety profile. It also said no interactions with other medications are known.

User Study Provides Commercial Backing

Calmino conducted a usability study involving 1,003 users. The study found PROIBS® was helpful for 94% of participants.

It also found 91% experienced an improvement in daily life. Meanwhile, 98% said they would recommend the product to someone else.

These figures came from a usability study rather than a clinical trial. The distinction matters when assessing the evidence presented for the product.

PROIBS® has been sold through the Swedish pharmacy market for more than a decade. Calmino said the product is also available in European markets and distributed internationally.

Expanding Beyond Travelan

Immuron is an Australian biopharmaceutical company focused on orally delivered targeted polyclonal antibodies for infectious diseases. PROIBS® adds a plant-derived medical device to its commercial digestive-health offering.

The US agreement follows what management described as rapid growth in US sales of Travelan®. That product already gives Immuron an established commercial presence in the country’s digestive-health category.

Chief Commercial Officer Flavio Palumbo said: “Following the rapid growth of Travelan® sales in the US, we have developed a commercial growth strategy to bring a portfolio of innovative digestive health products to market.”

He added: “PROIBS® is a great opportunity to further expand our digestive health portfolio by providing our customers with a proven premium product that delivers improvement in daily life.”

What Comes Next

The exclusive agreement gives Immuron responsibility for bringing PROIBS® into the US market. However, the announcement leaves the timing and economics of that rollout unspecified.

Execution will therefore be measured through subsequent launch details, distribution channels and reported sales. For now, the agreement expands Immuron’s relationship with Calmino from Australia into a second major geography.